Asenapine vs Quetiapine (Seroquel XR)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Asenapine
Marketed by AbbVie and partners
NCT00212784 · Phase 3 · completed
This 52-week trial randomly assigned 1,225 people with schizophrenia to asenapine or to olanzapine, with participants, carers, investigators and outcome assessors all unaware of assignment. The primary measure was change in total PANSS symptom score. Asenapine improved symptoms by 21.0 points against 27.5 points for olanzapine, a difference favouring olanzapine at p<0.0001, so asenapine was less effective than its active comparator on this measure.
Reported efficacy
Change in total PANSS score at endpoint (Screening, Week 76, 100, and once every 24 weeks thereafter until endpoint): Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint (unclear)
Result source: NCT00212771
Quetiapine (Seroquel XR)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00640601 · Phase 3 · completed
This was a nonrandomized, single-group, open-label study of 295 treated participants, without a placebo or active comparator. Although 56.88% were reported to have improved clinical benefit on the primary CGI-CB measure, the uncontrolled design cannot determine how much of the improvement was due to quetiapine rather than other factors.
Next expected readout: February 2032 · NCT07152184 (registry estimate)
Reported efficacy
Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Seroquel XR 56.88% (95% CI 50.8 to 62.8) (not_applicable)
Result source: NCT00640601
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Asenapine | Quetiapine (Seroquel XR) |
|---|---|---|
| PANSS total, change | -21.7 vs -16.2−5.5 vs placeboNCT0161718718 other results
| -24 vs -15.9−8.1 vs placeboNCT018103801 other result
|
| CGI-S, change | -1.2 vs -1−0.2 vs placeboNCT0161718717 other results
| -1.4 vs -0.9−0.5 vs placeboNCT018103801 other result
|
| PANSS response | 39.3% vs 20.7%+18.6 vs placeboNCT010981101 other result
| 62.7% vs 32.1%+30.6 vs placeboNCT01810380 |
| PSP, change | —Not posted · NCT00212771 | 15.3 vs 9.4+5.9 vs placeboNCT01810380 |
| Relapse (% of patients) | —Not posted · NCT00212771 | —Not posted · NCT00159770 |
PANSS total, change
- Asenapine
- -21.7 vs -16.2−5.5 vs placeboNCT01617187
18 other results
- -12.2 vs -0.9 NCT01098110
- -25.5 vs -17.8 NCT01190254
- -14.2 vs -0.9 NCT01098110
- -17.4 vs -16.2 NCT01617187
- -23.7 vs -17.8 NCT01190254
- -19 vs -15.4 NCT01617187
- -17.1 vs -15.5 NCT01617187
- -14.8 vs -13.2 NCT01617187
- -12.5 vs -10.7 NCT01617187
- -9.1 vs -7.1 NCT01617187
- -4.9 vs -4.8 NCT01617187
- -17 vs -15.4 NCT01617187
- -12.3 vs -15.5 NCT01617187
- -12 vs -13.2 NCT01617187
- -9.9 vs -10.7 NCT01617187
- -7.2 vs -7.1 NCT01617187
- -4 vs -4.8 NCT01617187
- -21 vs -27.5 NCT00212784
- Quetiapine (Seroquel XR)
- -24 vs -15.9−8.1 vs placeboNCT01810380
1 other result
- 102.3 vs 100.5 NCT00640562
CGI-S, change
- Asenapine
- -1.2 vs -1−0.2 vs placeboNCT01617187
17 other results
- -0.7 vs -0.2 NCT01098110
- -1.1 vs -0.8 NCT01617187
- -0.9 vs -0.8 NCT01617187
- -1.3 vs -0.8 NCT01190254
- -0.8 vs -0.7 NCT01617187
- -0.6 vs -0.5 NCT01617187
- -0.3 vs -0.3 NCT01617187
- -0.2 vs -0.2 NCT01617187
- -0.8 vs -0.2 NCT01098110
- -0.9 vs -1 NCT01617187
- -0.9 vs -0.8 NCT01617187
- -0.7 vs -0.8 NCT01617187
- -1.1 vs -0.8 NCT01190254
- -0.6 vs -0.7 NCT01617187
- -0.6 vs -0.5 NCT01617187
- -0.3 vs -0.3 NCT01617187
- -0.1 vs -0.2 NCT01617187
- Quetiapine (Seroquel XR)
- -1.4 vs -0.9−0.5 vs placeboNCT01810380
1 other result
- -1.5 vs -1.0 NCT00640562
PANSS response
- Asenapine
- 39.3% vs 20.7%+18.6 vs placeboNCT01098110
1 other result
- 43.8% vs 20.7% NCT01098110
- Quetiapine (Seroquel XR)
- 62.7% vs 32.1%+30.6 vs placeboNCT01810380
PSP, change
- Asenapine
- —Not posted · NCT00212771
- Quetiapine (Seroquel XR)
- 15.3 vs 9.4+5.9 vs placeboNCT01810380
Relapse (% of patients)
- Asenapine
- —Not posted · NCT00212771
- Quetiapine (Seroquel XR)
- —Not posted · NCT00159770
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety
Coverage. Asenapine: 14 of 14 rows · Quetiapine (Seroquel XR): 14 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Asenapine Rows use multiple source trials | Quetiapine (Seroquel XR) Rows use multiple source trials |
|---|---|---|
| CGI-I absolute value · score | 2.5 vs 3.1 placebo score @ 8wk5.0 mg BIDa,b,c,d NCT01190254 · Phase 3 · registry result, not featured evidence show 1 more dose2.8 vs 3.1 placebo score @ 8wk2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence | 91 vs 88 Risperidone score @ 12wkb,c,d NCT00640562 · Phase 3 |
| PANSS General Psychopathology absolute change · score | -10.1 vs -8 placebo score @ 6wk5 mg BIDa,b,c NCT01617187 · Phase 3 · registry result, not featured evidence show 1 more dose-8.9 vs -8 placebo score @ 6wk2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence | -11.6 vs -8.2 placebo score @ 6wkb,c NCT01810380 · Phase 3 · registry result, not featured evidence |
| PANSS Marder Anxiety Depression absolute change · score | -3.4 vs -3 placebo score @ 6wk5 mg BIDa,b,c NCT01617187 · Phase 3 · registry result, not featured evidence show 1 more dose-2.9 vs -3 placebo score @ 6wk2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence | -3.6 vs -2.9 placebo score @ 6wkb,c NCT01810380 · Phase 3 · registry result, not featured evidence |
| PANSS Marder Disorganized Thought absolute change · score | -4.3 vs -2.7 placebo score @ 6wk5 mg BIDa,b,c NCT01617187 · Phase 3 · registry result, not featured evidence show 1 more dose-3.8 vs -2.7 placebo score @ 6wk2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence | -4.8 vs -3.2 placebo score @ 6wkb,c NCT01810380 · Phase 3 · registry result, not featured evidence |
| PANSS Marder Negative absolute change · score | -4.7 vs -4 placebo score @ 6wk5 mg BIDa,b,c NCT01617187 · Phase 3 · registry result, not featured evidence show 1 more dose-3.4 vs -4 placebo score @ 6wk2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence | -4.8 vs -3.6 placebo score @ 6wkb,c NCT01810380 · Phase 3 · registry result, not featured evidence |
| PANSS Marder Positive absolute change · score | -7.6 vs -6.2 placebo score @ 6wk5 mg BIDa,b,c NCT01617187 · Phase 3 · registry result, not featured evidence show 1 more dose-6.8 vs -6.2 placebo score @ 6wk2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence | -8.4 vs -5.7 placebo score @ 6wkb,c NCT01810380 · Phase 3 · registry result, not featured evidence |
| PANSS Marder Uncontrolled Hostility/Excitement absolute change · score | -1.8 vs -1.1 placebo score @ 6wk5 mg BIDa,b,c NCT01617187 · Phase 3 · registry result, not featured evidence show 1 more dose-1.1 vs -1.1 placebo score @ 6wk2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence | -2.8 vs -1.8 placebo score @ 6wkb,c NCT01810380 · Phase 3 · registry result, not featured evidence |
| PANSS Negative Subscale absolute change · score | -4.9 vs -3.4 placebo score @ 8wk5.0 mg BIDa,b,c,e NCT01190254 · Phase 3 · registry result, not featured evidence show 1 more dose-4.8 vs -3.4 placebo score @ 8wk2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence | -4.5 vs -3.1 placebo score @ 6wkb,c,e NCT01810380 · Phase 3 · registry result, not featured evidence |
| PANSS Positive Subscale absolute change · score | -9.1 vs -6 placebo score @ 8wk5.0 mg BIDa,b,c,e NCT01190254 · Phase 3 · registry result, not featured evidence show 1 more dose-7.9 vs -6 placebo score @ 8wk2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence | -8.1 vs -5.4 placebo score @ 6wkb,c,e NCT01810380 · Phase 3 · registry result, not featured evidence |
| PANSS Total absolute change · score No placebo or comparator arm | -11.08 score @ 52wka,b,c NCT01244828 · Phase 3 · registry result, not featured evidence show 1 more dose-5.48 score NCT01244828 · Phase 3 · registry result, not featured evidence | 10.95 score @ 24wkb,c NCT00640601 · Phase 3 |
| Dropout rate | 44.4%5 mg twice dailyf NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results16.7%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 54.8%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 0%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 1%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 49.7% NCT01244828 · Phase 3 · registry result, not featured evidence 35.2%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 40.1%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 50%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 20.9%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 20.8%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 17.3%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 33.7% NCT00174265 · Phase 3 · registry result, not featured evidence 50.4% NCT00145496 · Phase 3 · registry result, not featured evidence 30.4% NCT00150176 · Phase 3 · registry result, not featured evidence 15.7% NCT00265343 · Phase 3 · registry result, not featured evidence 67.7% NCT00156065 · Phase 3 · registry result, not featured evidence 0%5 mg NCT01206517 · Phase 1 · registry result, not featured evidence 33.3%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 25%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | 38%f NCT00640601 · Phase 3 show 7 more results16.5% NCT00640562 · Phase 3 —Seroquel IR NCT01213836 · Phase 4 · registry result, not featured evidence —Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 20% NCT00954122 · Phase 4 · registry result, not featured evidence 30.2% NCT00779506 · Phase 4 · registry result, not featured evidence —Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence 20.8%Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 22.2%5 mg twice dailyf NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results0%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 22.3%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 0%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 0%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 23.6% NCT01244828 · Phase 3 · registry result, not featured evidence 17%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 17.6%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 0%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 5.1%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 7.5%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 6.1%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 8.1% NCT00174265 · Phase 3 · registry result, not featured evidence 17.2% NCT00145496 · Phase 3 · registry result, not featured evidence 8.2% NCT00150176 · Phase 3 · registry result, not featured evidence 7.5% NCT00265343 · Phase 3 · registry result, not featured evidence 11.8% NCT00156065 · Phase 3 · registry result, not featured evidence —5 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | 14.6%f NCT00640601 · Phase 3 show 7 more results7.3% NCT00640562 · Phase 3 —Seroquel IR NCT01213836 · Phase 4 · registry result, not featured evidence —Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 2.9% NCT00954122 · Phase 4 · registry result, not featured evidence 4.2% NCT00779506 · Phase 4 · registry result, not featured evidence —Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence 2.6%Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 0%5 mg twice dailyf NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results0%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 20.4%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 4.4%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 5.2%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 8.9% NCT01244828 · Phase 3 · registry result, not featured evidence 5.7%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 2.8%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 12.5%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 3.6%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 2.8%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 3.1%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 4.7% NCT00174265 · Phase 3 · registry result, not featured evidence 12.3% NCT00145496 · Phase 3 · registry result, not featured evidence 3.1% NCT00150176 · Phase 3 · registry result, not featured evidence 6.7% NCT00265343 · Phase 3 · registry result, not featured evidence 14.1% NCT00156065 · Phase 3 · registry result, not featured evidence 0%5 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | 11.2%f NCT00640601 · Phase 3 show 7 more results3.7% NCT00640562 · Phase 3 0%Seroquel IR NCT01213836 · Phase 4 · registry result, not featured evidence 0%Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 2.9% NCT00954122 · Phase 4 · registry result, not featured evidence 0% NCT00779506 · Phase 4 · registry result, not featured evidence 1.3%Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence —Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 5 mg twice dailyf daytime drowsiness 22.2% NCT01549041 · Phase 4 · registry result, not featured evidence show 19 more results10 mg daily in the evening daytime drowsiness 0% NCT01549041 · Phase 4 · registry result, not featured evidence 5/10 mg BID nasopharyngitis 21.7% schizophrenia 10.8% somnolence 10.8% NCT01142596 · Phase 3 · registry result, not featured evidence 5 mg BID insomnia 15% (placebo 13.9%) headache 8.8% (placebo 2%) anxiety 7.1% (placebo 11.9%) NCT01617187 · Phase 3 · registry result, not featured evidence 2.5 mg BID headache 10.3% (placebo 2%) insomnia 9.3% (placebo 13.9%) anxiety 7.2% (placebo 11.9%) NCT01617187 · Phase 3 · registry result, not featured evidence nasopharyngitis 21% somnolence 12.7% weight increased 12.7% NCT01244828 · Phase 3 · registry result, not featured evidence 5 mg BID akathisia 11.4% (placebo 5.2%) hypoaesthesia oral 10.9% (placebo 3.4%) insomnia 9.7% (placebo 12.1%) NCT01098110 · Phase 3 · registry result, not featured evidence 10 mg BID schizophrenia 13.8% (placebo 24.1%) somnolence 12.2% (placebo 1.7%) akathisia 10.5% (placebo 5.2%) NCT01098110 · Phase 3 · registry result, not featured evidence accidental overdose 12.5% acne 12.5% akathisia 12.5% NCT01190267 · Phase 3 · registry result, not featured evidence somnolence 14.8% headache 6.6% sedation 5.1% NCT01190267 · Phase 3 · registry result, not featured evidence 5.0 mg BID somnolence 17% (placebo 6.9%) sedation 11.3% (placebo 2%) insomnia 9.4% (placebo 5.9%) NCT01190254 · Phase 3 · registry result, not featured evidence 2.5 mg BID somnolence 20.4% (placebo 6.9%) dizziness 7.1% (placebo 1%) headache 7.1% (placebo 5.9%) NCT01190254 · Phase 3 · registry result, not featured evidence insomnia 10.6% weight increased 5.9% headache 2.4% NCT00174265 · Phase 3 · registry result, not featured evidence insomnia 17.6% somnolence 14.8% headache 13.5% NCT00145496 · Phase 3 · registry result, not featured evidence insomnia 20.1% (placebo 24.5%) somnolence 16% (placebo 17.2%) weight increased 14.4% (placebo 10.9%) NCT00150176 · Phase 3 · registry result, not featured evidence headache 5.2% influenza 5.2% schizophrenia 5.2% NCT00265343 · Phase 3 · registry result, not featured evidence insomnia 18.5% headache 10.9% parkinsonism 10.9% NCT00156065 · Phase 3 · registry result, not featured evidence 5 mg dystonia 66.7% dizziness 33.3% nausea 33.3% NCT01206517 · Phase 1 · registry result, not featured evidence 10 mg hypoaesthesia oral 50% dizziness 38.9% dysgeusia 38.9% NCT01206517 · Phase 1 · registry result, not featured evidence 2.5 mg sedation 33.3% dysgeusia 16.7% hypoaesthesia oral 16.7% NCT01206517 · Phase 1 · registry result, not featured evidence | show 5 more resultssomnolence 3.2% delusion 1.6% dizziness 1.6% NCT01213836 · Phase 4 · registry result, not featured evidence psychotic disorder 1.6% sedation 1.6% sleep disorder 1.6% NCT01213836 · Phase 4 · registry result, not featured evidence constipation 25.5% insomnia 23.4% sedation 12.8% NCT00779506 · Phase 4 · registry result, not featured evidence somnolence 22.2% (placebo 5%) weight increased 13.1% (placebo 3.7%) dizziness 11.8% (placebo 0.6%) NCT01810380 · Phase 3 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 12 weeks versus 8 weeks.
- eAssessment timepoints differ: 6 weeks versus 8 weeks.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Asenapine
show 1 more result
show 1 more result
show 17 more results
show 2 more results
show 19 more results
show 15 more results
show 15 more results
+ 21 further endpoints in the CSV export.
Quetiapine (Seroquel XR)
show 1 more result
show 1 more result
show 2 more results
show 1 more result
show 1 more result
show 1 more result
+ 9 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asenapine's landscape · Quetiapine (Seroquel XR)'s landscape